Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study  by Arakane, Ryo et al.
S
v
6
R
M
a
b
a
A
R
R
A
A
K
I
I
C
N
1
v
w
h
S
C
S
T
h
0
0Vaccine 33 (2015) 6650–6658
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
uperior  immunogenicity  proﬁle  of  the  new  intradermal  inﬂuenza
accine  compared  to  the  standard  subcutaneous  vaccine  in  subjects
5  years  and  older:  A  randomized  controlled  phase  III  study
yo  Arakanea, Ryosuke  Annakaa, Akiko  Takahamaa, Katsuyasu  Ishidaa,
ichiharu  Yoshiikea, Tetsuo  Nakayamab,  Fumihiko  Takeshitaa,∗
Daiichi Sankyo Co. Ltd., Japan
Kitasato Institute for Life Sciences, Laboratory of Viral Infection, Japan
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 10 July 2015
eceived in revised form 9 October 2015
ccepted 20 October 2015
vailable online 29 October 2015
eywords:
ntradermal vaccine
nﬂuenza
linical trial
ovel device
a  b  s  t  r  a  c  t
Background:  Although  the  elderly  are  at high  risk  for inﬂuenza,  the immunogenicity  in  the  elderly  is
lower  than  that  in  younger  adults.  We  developed  the  new  type of seasonal  inﬂuenza  vaccine  with  the
novel  intradermal  (ID)  injection  system.  In the  previous  exploratory  phase  I/II  study  of  the  ID vaccine
with  a dose  of  15  g HA  per strain  showed  the superior  immunogenicity  proﬁle  to that of  the  standard
subcutaneous  (SC)  injection  vaccine  in  subjects  aged  20 years  and  older.
Methods:  In this  multicenter,  randomized,  double-blind,  active  controlled  study,  900  adults  aged  65 years
and  older  were  randomized  at an  equal  ratio  to either  the  ID vaccine  group  or the  licensed  standard  SC
vaccine  group.  Immunogenicity  was  assessed  using  serum  hemagglutination  inhibition  (HAI)  titers.  The
co-primary  endpoints  were  the  geometrical  mean  titers  (GMT)  and  the  seroconversion  rates  (SCR)  of
HAI titers against  3  vaccine  strains  on Day  21 (21 days  after  vaccination).  To  evaluate  the  early  phase
immunogenicity,  the GMTs  and  SCRs  on Day  7  were  also  assessed  in  the  same  way  as  the  secondary
endpoints.
Results:  The  superiority  of  the  ID vaccine  in the  GMTs  and  SCRs  were  demonstrated  in  all  3 vaccine  strains
both  on Day  7 and  Day  21. The  frequency  of  any  injection-site  reactions  was  higher  in  the ID  vaccine
group,  while  the  severity  of  injection-site  reactions  and  the  frequency  of  systemic  AEs  were  comparable
between  the  ID  and  the SC  vaccine  groups.
Conclusions:  A  single-dose  of the  inﬂuenza  vaccine  with the  novel  ID injection  system  and  a  dose  of  15  g
HA was  suggested  as  an  appropriate  regimen  for clinical  use  in  inﬂuenza  prevention  and  associated
disease  burden  reduction.  It  was  also  suggested  that  the  new  ID  vaccine  has  the potential  to replace  the
standard  inﬂuenza  vaccine  from  the  view  point  of  immunogenicity  and  safety.
Trial registration:  JAPIC  Clinical  Trials  Information  (JapicCTI-142493).
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. IntroductionInﬂuenza is an acute respiratory illness caused by inﬂuenza
irus infection and has high morbidity and mortality world-
ide [1]. The elderly are at high risk relative to healthy young
Abbreviations: ID, intradermal; SC, subcutaneous; HA, hemagglutinin; HAI,
emagglutination inhibition; GMT, geometrical mean titer; GMTR, ratio of GMT;
CR, seroconversion ratio; SPR, seroprotection ratio; AE, adverse event; CHMP, The
ommittee for Medicinal Products for Human Use.
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adults because they are more vulnerable to death and hospital-
ization due to inﬂuenza and to the deterioration from underlying
diseases upon inﬂuenza infection [2]. Authorities in most devel-
oped countries including the United States and Japan recommend
inﬂuenza vaccination for the elderly. In Japan, people at 65
years and older are covered with the routine vaccination pro-
gram in the Preventive Vaccination Act [3]. The current standard
inﬂuenza vaccine in Japan is a subcutaneous (SC) injection
type and is used as a single or 2-dose regimen for all ages
except children under 6 months old. Although the immunogenic-
ity in the elderly is often lower than that in younger adults,
the dose of the inﬂuenza vaccine for the elderly is the same
15 g hemagglutinin (HA) per vaccine strain as for younger
adults [4].
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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To improve the immunogenicity of the seasonal inﬂuenza vac-
ine, a variety of approaches have been made, such as formulating
ith a new adjuvant [5], formulating with an increasing amount
f antigens [6], and changing administration route. Among several
ifferent routes of injection, the results of clinical studies using
ifferent types of intradermal (ID) injection devices or the Man-
oux technique have suggested that an ID delivery improves the
mmunogenicity of vaccines as compared with the standard vac-
ines delivered via intramuscular (IM) or SC route [7–10].
To deliver vaccine formulation to the dermis accurately and
onsistently, a novel ID injection system has been developed
Immucise®, Terumo Co., Tokyo, Japan). In addition, we  have
ecently conducted an exploratory, dose-ﬁnding, phase I/II clinical
tudy of the new seasonal inﬂuenza vaccine with this ID injection
ystem. In this phase I/II study, 600 adults aged 20 years and older
ere randomized to 6 study groups with subgroups of 300 young
dults (20–64 years old) and 300 older adults (65 years and older).
s a result, the serum geometric titer (GMT) of the HA inhibition
HAI) in the ID 15 g HA group were superior to those in the SC
5 g HA group on both Day 10 and Day 21 after the vaccination,
hile those in the ID 6 and ID 9 g HA groups were compara-
le with those in the SC 15 g HA group. The injection-site AEs
ere generally mild and transient, and did not occur in a dose or
osage-dependent manner.
Here we show the results of a conﬁrmatory phase III study
emonstrating the immunogenicity and the safety of the ID vaccine
ontaining 15 g HA by comparing it with the standard SC injec-
ion vaccine containing the same amount of HA (15 g) in Japanese
lderly aged 65 years and older.
. Material and methods
.1. Study design and objectives
This phase III, multicenter, randomized, double-blind, active
ontrolled study was performed at ﬁve study centers in Japan in
014. The objective of this study was to conﬁrm the immunolog-
cal non-inferiority of the ID vaccine to the standard SC injection
ype seasonal inﬂuenza vaccine in adults aged 65 years and older.
This study was performed under the double-blind, double-
ummy  design. The ID vaccine or ID placebo was  administered
n the deltoid area of the upper arm, while the SC vaccine or SC
lacebo was administered into an extensor side of the upper oppo-
ite arm. Since it is distinguishable between the investigational
accines and the placebo, the staff responsible for controlling, con-
itioning, and administration was kept independent from those
esponsible for the assessment of adverse events (AEs) to assure
lindness. Also, to keep the subjects from seeing the investigational
rug, the injection-sites were masked with the shielding cloth dur-
ng the administration procedure. Evaluators and vaccinators are
ompletely separated to keep blindness.
Nine-hundred subjects were randomized at an equal ratio to
ither the ID vaccine group or the SC vaccine group. The ran-
omization schedule was prepared by using a permuted block
andomization method (block size = 10). Gender and history of
nﬂuenza vaccine of last 2 seasons are deﬁned as stratiﬁcation fac-
ors. On Day 0, blood was taken before vaccination and then the
nvestigative drugs, either the combination of the ID vaccine and
he SC placebo or that of the ID placebo and the SC vaccine, were
dministered. Appearance of shock and anaphylaxis were checked
or 30 min  after the vaccination. On Day 7 and Day 21, blood was
aken in both groups.
This study was approved by the Institutional Review Boards of
ach study center. This study was conducted in accordance with3 (2015) 6650–6658 6651
Good Clinical Practice and the Declaration of Helsinki. Written
informed consent was  obtained from all subjects before enrollment.
2.2. Subjects
Healthy Japanese volunteers aged 65 years and older were
eligible to participate in this study. The main exclusion crite-
ria were: any history of seasonal inﬂuenza in the past 6
months, any seasonal inﬂuenza vaccination in the past 6
months, severe acute illness or febrile illness (over 37.5 ◦C),
hypersensitivity to elements of the inﬂuenza vaccine or the
new ID injection system, and any history of following dis-
ease: acute disseminating encephalomyelopathy, Guillain–Barre
syndrome, thrombocytopenic purpura, thrombocytopenia, vas-
culitis (Henoch–Schönlein purpura, Wegener’s granulomatosis,
leukocytoclastic vasculitis), encephalopathy/encephalitis, myelitis,
Stevens–Johnson syndrome, or nephrotic syndrome, administra-
tion with any live vaccine in the past 27 days, administration with
any inactivated/toxoid vaccine in the past 6 days, any history of
having a blood transfusion or administration with gamma globulin
in the past 3 months, any history of administration with more than
200 mg/kg of gamma  globulin in the past 6 months, administration
with any investigative drug in the past 4 months in clinical trials,
no intention to prevent pregnancy during this clinical trial, or being
judged as inadequate for joining the clinical trial by investigators.
2.3. Vaccines
All vaccines contained inactivated, trivalent, split-virion
inﬂuenza hemagglutinin (HA) derived from A/California/7/2009
(H1N1)pdm2009, A/Texas/50/2012(H3N2), and B/Massachusetts/
2/2012 vaccine strains recommended by the Ministry of Health,
Labor, and Welfare in Japan for the 2013/14 season. The ID vaccine
was administered with a dose of 0.1 mL containing 15 g HA per
strain per dose using the ID injection system (Immucise®, Terumo
Co., Tokyo, Japan). This system consists of a needle assembly with a
single 33-gauge needle with 1.15 mm  length and a preﬁlled syringe.
As a control, the licensed inﬂuenza vaccine was administered as an
SC dose of 0.5 mL  containing 15 g HA per strain per dose with
27-gauge needle.
2.4. Immunogenicity assessment
To evaluate immunogenicity, a hemagglutination inhibition
(HAI) assay was performed in VisMederi srl (Siena, Italy). HAI titer
was measured by using turkey blood cells and deﬁned as the recip-
rocal of the highest dilution at which hemaggulutin (HA) activity
was totally inhibited [11]. The titer of each sample was  calculated
as the average of its duplicate. The co-primary endpoints were the
differences in the seroconversion rates (SCRs, the percentage of
subjects with a pre-vaccination HAI titer <10 and post-vaccination
HAI titer ≥40 or a pre-vaccination HAI titer ≥1:10 and at least a
fourfold increase in post-vaccination HAI titer) and ratio of GMTs
between the ID and the SC vaccine groups on Day 21 against each of
the 3 vaccine strains. The differences on Day 7 were also assessed
as the secondary endpoints to evaluate the early phase immuno-
genicity. We  also conducted an evaluation according to the criteria
of The Committee for Medicinal Products for Human Use (CHMP)
for the annual licensure of seasonal inﬂuenza vaccines for adults
aged >60 years.2.5. Safety assessment
Solicited injection-site AEs (erythema, swelling, induration,
ecchymosis, pain, hotness, and pruritus) and systemic AEs (fever,
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Enroll ed and Randomized  (n =901) 
ID group 
ID 15 μg  (n = 451)  
SC group 
SC 15 μg (n = 450)  
Full  An alysis Set 
Immunogenicity (n = 450) 
Safety                 (n  = 450) 
Discontinuation 
Lost to follow- up (n = 0) 
Investigator’s decision (n =1)  
Discontinuation 
Lost  to  follow- up (n = 0)
Full  An alysis Set 
Immunogenicity (n = 450) 
Safety                 (n  = 450) 
F . All subjects completed the study. This phase III, multicenter, randomized, double-blind,
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Table 1
Demography of the study subjects.
ID 15 g
(n  = 450)
SC 15 g
(n = 450)
Sex, n (%)
Male 219 (48.7) 220 (48.9)
Female 231 (51.3) 230 (51.1)
Age,  years
Mean ± standard deviation 70.0 ± 4.15 70.0 ± 3.90
Range 65–88 65–82
History of Inﬂuenza vaccination,a n (%) 139 (30.9) 139 (30.9)
Data are for all vaccinated subjects. This phase III, multicenter, randomized, double-
blind, active controlled study was performed at ﬁve study centers in Japan in 2014.
a Subjects who  have previously received an inﬂuenza vaccination in the past 2
seasons (2012–2013, 2013–2014).ig. 1. Flow of subjects through the study. Subjects were randomized into 2 groups
ctive  controlled study was  performed at ﬁve study centers in Japan in 2014.
hivering, malaise, headache, and rash) were prelisted in the pro-
ided diary, and subjects spontaneously checked every day for 7
ays following the vaccination. Unsolicited AEs and serious AEs
SAEs) were also reported for 21 days following the vaccination. The
everity of injection site erythema, swelling, induration, and hem-
rrhage was graded by size (long-axis diameter) as mild (<2.0 cm),
oderate (2.0–5.0 cm), or severe (>5.0 cm), while that of fever was
raded as mild (37.5–37.9 ◦C), moderate (38.0–38.9 ◦C), or severe
≥39.0 ◦C). All other AEs were classiﬁed as mild (for no interfer-
nce with daily activity and easily tolerated), moderate (for some
nterference with daily activity), or severe (for incapacitating con-
ition).
.6. Criteria and statistical methods
According to the United States Food and Drug Administra-
ion (FDA) criteria for licensure of seasonal inﬂuenza vaccines,
he potency of a new vaccine is judged based on the serum
AI titer induced by the new vaccine as compared with
hat by the licensed vaccine: (1) the upper bound of the 2-
ided 95% conﬁdential interval (CI) on the ratio of the GMTs
GMTU.S. licensed vaccine/GMTnew vaccine) should not exceed 1.5. (2) The
pper bound of the 2-sided 95% CI on the difference between
he SCRs (SCRU.S. licensed vaccine − SCRnew vaccine) should not exceed
0% points, which had been used to conﬁrm the non-inferiority of
everal new vaccines [12–17]. Based on such criteria, we set the
odiﬁed criteria for conﬁrmation of the non-inferiority of the ID
accine to the standard SC vaccine as follows: based on serum HAI
iters on Day 21, (1) the lower bound of the 95% CI on the difference
etween the SCRs (SCR in the ID vaccine group − SCR in the SC vac-
ine group) is greater than −10% and (2) the ratio of GMTs (GMT in
he ID vaccine group/GMT in the SC vaccine group) is greater than
/3.
According to the previous phase I/II study of this new ID vaccine,
t was hypothesized that the SCR induced by the ID vaccine is supe-
ior to that by the SC vaccine. To demonstrate the non-inferiority
f both the SCR and GMT  as a co-primary endpoint, the power was
stimated based on the results of the phase I/II study. The power cal-
ulated using the results of the phase I/II study was 99.6% for H1N1
train, 95.1% for H3N2 strain, and 97.2% for B strain, indicating that
he estimated power to meet for all 3 strains was 92%. Finally, in
erms of assessing the safety, the sample size of 450 subjects in each
roup was considered to be enough to meet the FDA guidance [12].Once the non-inferiority was statistically conﬁrmed, we planned
to assess the superiority of the ID vaccine to the SC vaccine in accor-
dance with the following criteria: (1) the lower bound of the 95% CI
difference on the difference between the SCRs (SCR in the ID vaccine
group − SCR in the SC vaccine group) is greater than 0% and (2) the
ratio of GMTs (GMT in the ID vaccine group/GMT in the SC vaccine
group) is greater than 1 [12]. Statistical analyses were performed
with SAS® version 9.2 (SAS Institute, Cary, NC, USA).
3. Result
3.1. Study population
From April to May  in 2014, 901 subjects were enrolled and
randomized into the ID (n = 451) and the standard SC vaccine
(n = 450) groups. One subjects discontinued during the study period
due to Investigator’s decision before vaccination. This subject was
replaced with another subject who was  assigned randomly (Fig. 1).
The demography and baseline characteristics were comparable
between the 2 groups (Table 1). The distribution of age, the sex ratio,
and the frequency of those having history of seasonal inﬂuenza
vaccination in the past 2 seasons (2012/2013 and 2013/2014) were
also comparable between the 2 groups. No subjects had any history
of seasonal inﬂuenza infection in the 2013/2014 season.
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Table  2
Non-inferiority and Superiority of ID to SC.
Strain Day 7 Day 21
ID
(n = 450)
SC
(n = 450)
ID
(n = 450)
SC
(n = 450)
A/H1N1
SCR, % (95% CI) 59.8 (55.1, 64.3) 42.3 (37.7, 47.0) 72.2 (67.8, 76.3) 61.6 (56.9, 66.1)
SCR  difference (95% CI) 17.5 (11.0, 23.8) – 10.7 (4.5, 16.7) –
Non-inferiorityb a – a –
Superiorityc a – a –
GMT  (95% CI) 136.5 (118.8, 156.9) 76.9 (66.8, 88.5) 224.5 (201.0, 250.8) 155.4 (137.3, 175.9)
GMTR  (95% CI) 1.8 (1.5, 2.2) – 1.5 (1.2, 1.7) –
Non-inferiorityd a – a –
Superioritye a – a –
A/H3N2
SCR,  % (95% CI) 58.7 (54.0, 63.3) 45.7 (41.0, 50.4) 68.4 (63.9, 72.7) 59.1 (54.4, 63.7)
SCR  difference (95% CI) 13.0 (6.5, 19.4) – 9.3 (3.1, 15.5) –
Non-inferiorityb a – a –
Superiorityc a – a –
GMT  (95% CI) 266.2 (231.7, 305.9) 145.1 (124.8, 168.6) 437.1 (391.1, 488.6) 286.4 (249.8, 328.4)
GMTR  (95% CI) 1.8 (1.5, 2.3) – 1.5 (1.3, 1.8) –
Non-inferiorityd a – a –
Superioritye a – a –
B
SCR,  % (95% CI) 37.8 (33.3, 42.4) 25.4 (21.4, 29.7) 55.1 (50.4, 59.8) 46.7 (42.0, 51.4)
SCR  difference (95% CI) 12.4 (6.3, 18.3) – 8.4 (1.9, 14.9) –
Non-inferiorityb a – a –
Superiorityc a – a –
GMT  (95% CI) 21.0 (18.7, 23.7) 14.8 (13.3, 16.5) 35.3 (31.1, 40.0) 27.0 (23.8, 30.6)
GMTR  (95% CI) 1.4 (1.2, 1.7) – 1.3 (1.1, 1.6) –
Non-inferiorityd a – a –
Superioritye a – a –
This phase III, multicenter, randomized, double-blind, active controlled study was performed at ﬁve study centers in Japan in 2014. The subjects were 65 years and older.
a Met  the superiority criteria or non-inferiority criteria.
b Non-inferiority was deﬁned as having the lower bound of the 2-sided 95% CIs for the HAI antibody SCR difference (ID minus SC) ≥−10.0 for each strain.
c Superiority was deﬁned as having the lower bound of the 2-sided 95% CIs for the HAI antibody SCR difference (ID minus SC) >0 for each strain.
d Non-inferiority was deﬁned as having the lower bound of the 2-sided 95% CIs for the HAI antibody GMT ratio (ID divided by SC) ≥2/3 for each strain.
e Superiority was deﬁned as having the lower bound of the 2-sided 95% CIs for the HAI antibody GMT  ratio (ID divided by SC) >1 for each strain.
Table 3
Comparison of immunogenicity outcomes between ID and SC.
Strain Immunogenicity criteriaa ID
(n = 450)
SC
(n = 450)
A/H1N1
GMT (95% CI) Day 0 17.3 (15.1–19.8) 17.6 (15.3–20.2)
SCR,  % (95% CI) >30% Day 7 59.8%b (55.1, 64.3) 42.3%b (37.7, 47.0)
Day  21 72.2%b (67.8, 76.3) 61.6%b (56.9, 66.1)
GMTR (95% CI) >2.0 Day 7 7.9b (6.5, 9.6) 4.4b (3.6, 5.3)
Day  21 13.0b (10.9, 15.5) 8.9b (7.4, 10.7)
SPR,  % (95% CI) >60% Day 7 86.4%b (82.9, 89.5) 74.4%b (70.1, 78.4)
Day 21 95.3%b (93.0, 97.1) 89.3%b (86.1, 92.0)
A/H3N2
GMT  (95% CI) Day 0 32.9 (27.8–38.9) 29.5 (24.9–34.9)
SCR,  % (95% CI) >30% Day 7 58.7%b (54.0, 63.3) 45.7%b (41.0, 50.4)
Day 21 68.4%b (63.9, 72.7) 59.1%b (54.4, 63.7)
GMTR (95% CI) >2.0 Day 7 8.1b (6.5, 10.1) 4.9b (3.9, 6.1)
Day  21 13.3b (10.9, 16.3) 9.7b (7.8, 12.1)
SPR,  % (95% CI) >60% Day 7 91.1%b (88.1, 93.6) 83.7%b (80.0, 87.0)
Day 21 96.2%b (94.0, 97.8) 92.0%b (89.1, 94.3)
B
GMT  (95% CI) Day 0 7.5 (7.0–8.0) 7.5 (7.0–8.0)
SCR,  % (95% CI) >30% Day 7 37.8%b (33.3, 42.4) 25.4% (21.4, 29.7)
Day  21 55.1%b (50.4, 59.8) 46.7%b (42.0, 51.4)
GMTR (95% CI) >2.0 Day 7 2.8b (2.5, 3.2) 2.0 (1.7, 2.3)
Day 21 4.7b (4.1, 5.5) 3.6b (3.1, 4.2)
SPR,  % (95% CI) >60% Day 7 49.6% (44.8, 54.3) 35.9% (31.4, 40.5)
Day  21 64.2%b (59.6, 68.7) 56.4% (51.7, 61.1)
This phase III, multicenter, randomized, double-blind, active controlled study was performed at ﬁve study centers in Japan in 2014. The subjects were 65 years and older.
CI,  conﬁdence interval; GMT, geometric mean titer; GMTR, geometric mean titer ratio; SCR, seroconversion rate (proportion with a pre-vaccination titer <1:10 and a post-
vaccination titer ≥1:40; or a pre-vaccination titer ≥1:10 and at least a fourfold increase in a post-vaccination titer); SPR seroprotection rate (percentage of participants with
a  post-vaccination titer ≥40)
a The European Union Committee for Medicinal Products for Human Use (CHMP) criteria deﬁned for people aged >60.
b Met CHMP criteria.
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Table 4
Reactogenicity of ID and SC: number and proportion of participants experiencing injection site reactions.
ID SC
Active Placebo Active Placebo
Injection site reactions, n (%)
Any 419 (93.1) 69 (15.3) 223 (49.6) 77 (17.1)
Solicited injection site reactions
Erythema
Mild 197 (43.8) 44 (9.8) 55 (12.2) 46 (10.2)
Moderate 179 (39.8) 4 (0.9) 85 (18.9) 5 (1.1)
Severe 31 (6.9) 0 (0.0) 41 (9.1) 1 (0.2)
Swelling
Mild  127 (28.2) 10 (2.2) 21 (4.7) 14 (3.1)
Moderate 86 (19.1) 0 (0.0) 51 (11.3) 6 (1.3)
Severe 13 (2.9) 0 (0.0) 21 (4.7) 0 (0.0)
Induration
Mild  82 (18.2) 8 (1.8) 14 (3.1) 3 (0.7)
Moderate 41 (9.1) 0 (0.0) 40 (8.9) 3 (0.7)
Severe 4 (0.9) 0 (0.0) 6 (1.3) 0 (0.0)
Ecchymosis
Mild  3 (0.7) 4 (0.9) 5 (1.1) 3 (0.7)
Moderate 3 (0.7) 3 (0.7) 6 (1.3) 0 (0.0)
Severe 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Pain
Mild  70 (15.6) 7 (1.6) 75 (16.7) 13 (2.9)
Moderate 3 (0.7) 0 (0.0) 1 (0.2) 0 (0.0)
Severe 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hotness
Mild  120 (26.7) 9 (2.0) 76 (16.9) 6 (1.3)
Moderate 1 (0.2) 0 (0.0) 1 (0.2) 0 (0.0)
Severe 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Pruritus
Mild  167 (37.1) 12 (2.7) 78 (11.3) 11 (2.4)
Moderate 3 (0.7) 0 (0.0) 1 (0.2) 0 (0.0)
Severe 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Solicited injection site reaction proﬁle after ID or SC vaccination.
Placebo of ID are administered subcutaneously and Placebo of SC are administered intradermally.
S is: mild <2.0 cm,  moderate 2.0–5.0 cm,  severe >5 cm;  pain, hotness, pruritus: mild = easily
t severe = unable to perform usual activities.
P d by the number of subjects.
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Table 5
Reactogenicity of ID and SC: number and proportion of participants experiencing
systemic reactions.
ID SC
Systemic reactions, n (%)
Any 64 (14.2) 58 (12.9)
Solicited systemic reactions
Fever
Mild 3 (0.7) 0 (0.0)
Moderate 0 (0.0) 0 (0.0)
Severe 0 (0.0) 0 (0.0)
Shivering
Mild 12 (2.7) 12 (2.7)
Moderate 0 (0.0) 1 (0.2)
Severe 0 (0.0) 0 (0.0)
Malaise
Mild 39 (8.7) 35 (7.8)
Moderate 1 (0.2) 5 (1.1)
Severe 0 (0.0) 0 (0.0)
Headache
Mild 23 (5.1) 31 (6.9)
Moderate 0 (0.0) 4 (0.9)
Severe 0 (0.0) 0 (0.0)
Rash
Mild 2 (0.4) 0 (0.0)
Moderate 1 (0.2) 1 (0.2)
Severe 0 (0.0) 0 (0.0)
Systemic reaction proﬁle after ID or SC vaccination.
Severity according to the following scale: fever: mild 37.5–37.9 ◦C, moderate
38.0–38.9 ◦C, severe ≥39.0 ◦C; shivering, malaise, headache, rash: mild = easily tol-everity according to the following scale: erythema, swelling, induration, ecchymos
olerated, moderate = sufﬁciently discomforting to interfere with normal activities, 
ercentages are calculated as the number of participants reporting the event divide
.2. Immunogenicity
The non-inferiority of the ID vaccine to the standard SC vaccine
as conﬁrmed for all 3 vaccine strains on Day 21 (Table 2). When
AI titers on both Day 7 and Day 21 were evaluated, both the SCRs
nd GMTRs in the ID vaccine group were shown to be superior to
hose in the SC vaccine group for all 3 vaccine strains (Table 2). As
hown in Table 3, the results of HAI titers in the ID vaccine group
et the CHMP criteria for all 3 vaccine strains.
The reverse cumulative distribution curves of HAI titers on Day
, Day 7 and Day 21 are shown in Fig. 2. The distribution patterns
f HAI titers on Day 0 were comparable between the 2 groups. In
ccordance with the difference of the GMT  after the vaccination,
 shift to the right was larger in the ID vaccine group than that in
he SC vaccine group on Day 7. The distribution patterns in the ID
accine group on Day 7 were comparable to those in the SC vac-
ine group on Day 21, in particular for the H1N1 and the H3N2
trains, suggesting that the ID vaccine induced approximately 2
eeks faster HAI activity than the standard SC vaccine.
.3. Safety
No major concerns were found in the safety results in both
he ID and SC vaccine groups. Both vaccines were well tolerated
Tables 4 and 5)..3.1. Total AEs
The frequency of any injection-site AEs in the ID vaccine group
as higher than that in the SC vaccine group (93.3% vs. 57.8%). Since
erated, moderate = sufﬁciently discomforting to interfere with normal activities,
severe = unable to perform usual activities.
Percentages are calculated as the number of participants reporting the event divided
by  the number of subjects.
R. Arakane et al. / Vaccine 33 (2015) 6650–6658 6655
Fig. 2. Reverse cumulative frequency distribution of HAI titer. Circles show HI titers at Day 0, triangles show HI titers at Day 7, and squares show HI titers at Day 21. Pink
shows  HI titers in the ID vaccine group and blue shows HI titers in the SC vaccine group.
6656 R. Arakane et al. / Vaccine 33 (2015) 6650–6658
Fig. 3. Solicited AEs for the vaccine injection-sites proﬁle of ID and SC vaccine group. Data show that the daily rate of injection-sites AEs. Pink shows data in the ID vaccine
group  and blue shows data in the SC vaccine group.
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his study was  performed under the double-blind, double-dummy
esign, the results enabled us to perform analysis of the injection-
ite AEs for both the vaccine and the placebo in the same subject at
lmost the same time (Table 4).
.3.2. Injection-site AEs
Regarding solicited AEs for the vaccine injection-sites, the fre-
uency of the ID injection-sites in the ID vaccine group (93.1%) was
igher than that of the SC injection-site in the SC vaccine group
49.6%). Erythema was the most common AE in both groups and
he frequency in the ID vaccine group (90.4%) was  almost twice as
uch as that in the SC vaccine group (40.2%). Not only erythema
ut also other AEs including swelling, induration, ecchymosis, hot-
ess and pruritus were more frequently observed in the ID vaccine
roup, while pain occurred at a similar rate in both groups. The
everities of most types of the injection-site AEs in the ID vaccine
roup were mild or moderate and the frequencies of severe types of
rythema, swelling, induration, and ecchymosis were comparable
etween both groups (Table 4).
Time course analysis shows that the frequency of solicited
njection-site AEs in both groups peaked at 3 days after the vac-
ination and decreased over time, indicating that the injection-site
eactions occur transiently (Fig. 3). Four reactions with three reac-
ions of erythema and one reaction of induration in the ID vaccine
roup lasted more than 2 months (up to 107 days in erythema),
esulting in a resolution without any medical treatments.
The frequencies and severities of the injection-site AEs followed
y either ID or SC injection with the vaccine were higher than those
ith the placebo, suggesting that injection-site reactions were
ooperatively upregulated by the injection itself and the vaccine
ngredients.
.3.3. Solicited systemic AEs
The frequencies and the severities of systemic AEs in the ID vac-
ine group were comparable with those in the SC vaccine group,
uggesting that the new ID vaccine is as safe as the standard SC
accine. Among systemic AEs, malaise was the most frequently
bserved (8.9% in both groups) and its severities were comparable
etween both groups.
A joint dislocation was the only SAE that occurred during the
tudy period, which was not considered related to the investiga-
ional vaccine. No subjects withdrew due to any AEs in this study.
. Discussion
Consistent with the previous exploratory phase I/II study, it was
roved in this conﬁrmatory phase III study that the inﬂuenza HA
accine with the novel ID injection system induces higher serum
evels of HAI titer for all 3 vaccine strains than the standard SC injec-
ion vaccine. Such high levels of antibody responses were induced
ithin 7 days after the vaccination. In previous phase I/II study of
he ID inﬂuenza vaccine, we investigated antibody responses at Day
0 and the result showed similar to those at Day 7 of this phase
II study. Based on publicly available information, such antibody
esponses at earlier time points less than Day 10 have never been
nvestigated in other studies of ID inﬂuenza vaccines.
The results of past clinical studies have suggested that an ID
njection of marketed vaccines originally formulated for SC or IM
njection has the potential to induce the efﬁcacy superior to that
nduced by the original dosing. Accuracy and consistency of an ID
elivery, however, depend on the performance of device, which
ould be a key to an opportunity for universal use of the IDype of vaccines as an improved vaccination method in the mar-
et. The ID injection system used in this study has a needle with
.15 mm in length to insert perpendicularly to the skin. This length
s designed to stay proper depth for ID injection according to the3 (2015) 6650–6658 6657
results of previous human skin studies [18,19]. Previous studies
using animal models have shown the mechanistic differences in the
immunogenicity following an antigen delivery to ID and to other
injection-sites, i.e., SC and IM.
Regarding immunogenicity of ID inﬂuenza vaccines, the results
of several different clinical studies in the elderly aged 65 years and
older showed that as compared with the licensed non-adjuvanted
IM inﬂuenza vaccine or the licensed virosomal IM inﬂuenza vaccine,
the licensed ID inﬂuenza vaccine induced same or higher levels of
antibody responses, i.e., higher HI and NT titers against H3N2 or B
vaccine strain, while comparable titers against H1N1 strain, higher
cross-clade antibody responses to H3N2, and higher prevention
rate of hospitalization due to inﬂuenza virus infection [20–22]. The
differences between the results of present study and other stud-
ies may  be due to differences in the accuracy and consistency of
ID administration, i.e., different ID administration devices used in
the studies, vaccine strains used in the studies, and administration
routes of control vaccines, i.e., SC in the present study and IM in
other studies.
In a recent clinical research, safety and acceptance of 3 different
types of licensed inﬂuenza vaccines, i.e., the ID vaccine formulated
with HA antigens, the IM vaccine formulated with HA antigens
plus MF-59 adjuvant, and the IM vaccine formulated with HA anti-
gens alone, were compared in the elderly population aged 65 years
and older [23]. In accordance with other studies [10,24,25], the
occurrence rate of local inﬂammation was the highest in the ID
vaccine group, although severities of such AEs were generally mild
and local inﬂammation was  transient. In contrast, participants’
responses to the tolerability questionnaires indicated that both the
discomfort associated with the vaccination and any subsequent AEs
were readily tolerable. Pain accompanied vaccine administrations
at similar rates with all 3 products.
It has been demonstrated that several new types of inﬂuenza
vaccines, such as those formulated with a new adjuvant or with a
higher amount of HA, i.e., 60 g HA per strain, have unique pro-
ﬁles in terms of immunogenicity and safety [5,6]. Relative to such
new products, it was suggested that our new ID vaccine has advan-
tages of not only superior immunogenicity but also assured safety
since the formulation of the new ID vaccine is comparable with
the standard inﬂuenza HA vaccine having a history of more than
30-year clinical use.
Consistent with the result of the phase I/II study, the frequency
of any injection-site reactions was higher as compared with the SC
injection-type vaccine, although the formulations were compara-
ble (data not shown). Since the injection-site AEs are evaluated in
part by appearance of the skin, they may  not be correlated with a
net inﬂammation in the site where the antigen is delivered, i.e., the
inﬂammation occurred in the subcutis may  be less reﬂected in the
appearance of the skin surface as compared with that in the der-
mis. In fact, we examined the local irritation using a rabbit model by
evaluation of the appearance of the injection-sites and histopatho-
logical analysis after the ID dosing and the SC dosing of the same
amount of inﬂuenza HA. The results showed that although the
histopathological changes were similar, the local irritation scores
examined based on the appearance of the skin were higher after
the ID dosing than after the SC dosing (data not shown).
5. Conclusion
The new type of seasonal inﬂuenza vaccine with the novel ID
injection system and a dose of 15 g HA per strain induced higher
HAI titers in the elderly aged 65 years and older as compared
with the standard SC vaccine. Although the frequency of any
injection-site AEs was higher in the ID vaccine group, severity
of the injection-site AEs and the frequency of systemic AEs were
6 cine 3
c
t
t
p
A
d
D
h
p
D
b
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[658 R. Arakane et al. / Vac
omparable between the ID and the SC vaccine groups. Taken
ogether, it was suggested that this new ID vaccine has the poten-
ial to take over the standard inﬂuenza vaccine from the view
oint of immunogenicity and safety.
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